Molecular Profile | Unknown unknown |
Therapy | ETC-159 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | not applicable |
Create By | spatt |
Update By | spatt |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Advanced Solid Tumor | not applicable | ETC-159 | Phase I | Actionable | In a Phase I trial, treatment with ETC-159 was well-tolerated, decreased Wnt signaling, and resulted in stable disease in 2 out of 16 treated patients with advanced solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2584)). | detail... |
---|
PubMed Id | Reference Title | Details |
---|---|---|
First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours | Full reference... |